查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835063

女性用避孕市场依产品类型、机制、最终用户年龄和通路划分－2025-2032 年全球预测

Female Contraceptive Market by Product Type, Mechanism, End User Age, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，女性用避孕市场规模将成长至 165.3 亿美元，复合年增长率为 6.60%。

主要市场统计数据
基准年2024年 99.1亿美元
预计2025年 105.7亿美元
预测年份：2032年 165.3亿美元
复合年增长率（%） 6.60%

策略介绍，阐述影响现代女性用避孕器决策的临床进展、相关人员的优先事项和获取限制

随着临床创新、医疗服务提供者的转变以及患者期望的不断变化，女性避孕的格局正在迅速演变。本报告首先简要阐述了当代环境，重点介绍了临床模式、分销现状、监管压力以及影响医疗机构避孕可及性和采用率的实际限制因素。报告还将观察到的医疗服务提供者偏好和患者决策模式与设备和药物选择的最新进展相结合，为企业高管和临床领导者奠定了实用的知识基准。

引言部分重点阐述了技术改进、以患者为中心的医疗模式和供应链韧性如何相互交织，从而确定了最有价值的投资和营运重点，从而将竞争格局置于背景之中。引言也明确了关键的相关人员群体（製造商、临床医生、相关人员、采购团队和病患权益组织），并阐明了每个群体所掌控的决策槓桿。该框架将帮助读者理解后续章节，包括结构性变化、政策影响、细分市场细微差别、区域动态和建议行动。

分析概述了正在重塑避孕实践模式和患者在医疗环境中获取避孕药具的临床、监管和数位力量的融合

一系列变革力量正在重塑女性避孕领域，这些力量正在改变临床实践、产品开发和患者的选择。新的设备设计和长效製剂正在为各个生殖生命阶段的临床选择提供更多选择，并促使临床医生重新思考咨询工作流程和追踪通讯协定。同时，数位健康工具和远端医疗已开始改变避孕咨询、配药和追踪的提供方式，减少了地域差异，并使患者能够自主选择避孕方法。

除了技术和医疗服务的变化之外，监管途径和证据预期也在不断演变，这提高了临床数据的标准，同时也明确了产品标籤扩展和新适应症的窗口期。随着各公司追求差异化的价值提案，强调易用性、副作用概况和整合的护理体验，而非仅仅在价格上竞争，竞争动态正在改变。最后，付款方方式和公共卫生优先事项越来越注重可及性和依从性支持计画的公平性，这促使相关人员设计解决方案，以解决持续和适当使用避孕药具的系统性障碍。这些转变，加上持续的普及，需要整合商业和临床策略，以协调产品差异化、报销参与和医疗机构教育。

全面分析2025年关税调整将如何重塑避孕药具的供应链、筹资策略与定价压力

2025年的政策环境引入了影响进口药品投入和设备零件的关税调整，这些变化对采购、定价动态和供应链配置产生了复合影响。依赖国际采购电子元件製造可植入设备或依赖海外生产的原料药的製造商面临着直接的利润压力，引发了关于近岸外包、供应商多元化和库存策略的讨论。采购负责人和医院系统正在透过审查供应商合约并探索更长的采购期限来应对波动。

这些关税主导的成本压力也影响产品生命週期决策。开发团队优先考虑流程效率和供应商整合，以便在更高的落地成本下也能维持产品可行性。同时，预算有限的公共卫生项目和安全网提供者正在探索补充资金模式和采购联盟，以维持产品的可及性，特别是对于需要专门植入培训和设备供应的长效可逆避孕药。重要的是，一些製造商已加快步伐，透过在地化关键投入品的生产，并重新设计包装和物流，以提高韧性并缩短前置作业时间，从而降低跨境关税的影响。

从需求角度来看，临床医生和采购主管指出，在製剂和采购指南受到严格限制的环境下，即使交付成本略有上涨，也会影响咨询偏好。因此，商业团队必须将资费方案纳入采购谈判、定价策略和价值沟通中，强调医疗总成本、依从性偏好，从而引起付款人和机构买家的共鸣。实现供应链多元化并向区域产能转移是一项需要多年努力的工作，但在不断变化的贸易环境中，稳定医疗资源取得并保持竞争力正日益成为当务之急。

将产品类型、荷尔蒙机制、年龄层和分销管道联繫起来的详细细分洞察，以揭示临床和商业结合的目标机会

有效的细分可以揭示避孕生态系中临床效益、病人偏好和机会的交会点。植入、注射、避孕器和避孕药是核心临床类别，每种类别都有不同的给药途径和遵从性。对于避孕器，区分含铜和荷尔蒙的配方会影响副作用管理、有效持续时间和提供者训练。避孕药有复方製剂和仅含黄体素的配方，即使是复方製剂，不同世代之间也有差异。第一代、第二代、第三代和第四代药物各有其独特的功效和耐受性权衡，影响配方师的选择。

按机制细分，透过区分荷尔蒙疗法和非荷尔蒙疗法选项，并认识到荷尔蒙疗法选项分为组合药物製剂和仅含孕激素的製剂，具有不同的禁忌症和咨询需求，进一步明确了需求动态。 15-24 岁族群优先考虑自主性、便利性和隐私性；25-34 岁族群通常会在计划生育目标与职业和生活方式之间取得平衡；35-49 岁族群优先考虑长期疗效、併发症考量以及过渡到合适的非动态选项。分销管道塑造了获取途径，诊所、医院药房、线上药房和零售药房各自描述了明确的摩擦点以及教育、依从性支援和后续护理的机会。

整合这些细分市场，可以揭示哪些有针对性的干预措施可以提高药物的采用率和留存率。例如，长效製剂可能与寻求最低维护的老年人群产生强烈共鸣，而数位咨询和邮购配送则可以显着降低优先考虑谨慎的年轻用户的获取门槛。同样，根据特定机制的安全考虑客製化沟通方式，并确保分销管道支援药物的插入和给药，也是关键的营运重点。透过在产品类型、机制、年龄和分销管道的交叉领域协调产品差异化、临床证据产生和通路赋能，相关人员可以製定更有针对性、更有效的策略，以兼顾临床结果和使用者体验。

比较美洲、中东和非洲以及亚太地区影响取得途径、监管途径和分销策略的关键区域动态和政策

地理动态影响药物的可及性、监管途径和竞争行为，为每个地区带来了独特的限制和机会。在美洲，政策争议、付款人结构和多样化的医疗服务提供者网络既为资源充足的医疗体系中的快速商业化创造了机会，也为服务不足的人群带来了持续的可及性挑战。区域采购倡议和倡议计画决定了公共医疗机构对药物的接受程度，而与私人付款人的谈判则决定了产品在高报销水平环境中的布局。

欧洲、中东和非洲呈现出复杂的法规环境和能力差异。在这一广大区域内，一些国家拥有高度集中的采购和严格的监管协调，一旦获得核准，即可进行协调部署。其他市场则呈现细分化，不同的临床实务模式和基础设施影响器械避孕器的可行性。获取计画和国际捐助倡议在推动长效可逆避孕措施的广泛传播方面仍然发挥着重要作用，尤其是在资源匮乏的地区。

亚太地区拥有雄厚的製造能力，国内需求快速成长。一些司法管辖区的监管机构正在加快避孕产品的审查，并培养本地製造能力，从而缩短前置作业时间，并增加对国际贸易波动的承受能力。然而，文化因素、医疗保健提供者的执业规范以及差异化的报销格局仍然影响着采用曲线。在所有地区，相关人员必须根据当地的法律规范、分销生态系统以及影响采购和患者可及性的政策重点调整其商业化策略。

对製造商、设备专家和敏捷参与企业如何透过临床证据、伙伴关係和供应链弹性实现差异化进行实际分析

竞争格局由传统製药公司、单一业务设备製造商以及利用服务和数位生态系统来提升可及性的新参与企业组成。领先的公司专注于研发，以提高耐受性和易用性，同时投资培训项目，帮助临床医生掌握设备插入和追踪技能。製造商与临床网路之间的策略伙伴关係正成为一种可行的途径，透过将产品供应与医疗保健提供者的教育和病患支援服务相结合，加速医疗应用。

规模较小、更敏捷的公司正凭藉创新的交付机制、患者参与工具以及针对特定年龄层或临床亚群的利基策略脱颖而出。製造外包联盟和集团采购组织正在透过谈判长期供应协议来增强影响力，这凸显了可预测的供应和基于价值的合约对于商业性成功的重要性。

总体而言，成功的公司将能够将产品属性与可证明的临床和经济效益相结合，投资于上市后和现实世界证据，并建立涵盖临床医生培训和患者支持的综合价值命题。在製造、监管策略和分销方面的卓越营运也同样重要；这些环节的中断会迅速削弱医疗保健买家和临床医生的信任。

製造商和医疗系统领导者可采取的策略重点，以协调证据产生、弹性供应链和特定管道的商业性执行

产业领导者应在临床证据产生、供应链韧性和特定管道商业化之间采取协调一致的策略。首先，投资于可靠的比较安全性和耐受性数据，这些数据能够直接解决临床医生的担忧并反映患者相关的疗效，并将这些证据与简洁易懂、方便临床医生使用的教育模组相结合，以加速基于器械的治疗和长效治疗方案的顺利应用。其次，优先考虑供应商多元化，并考虑投资区域製造或与製造外包製造商合作，以降低贸易政策变化和投入成本波动带来的风险。

第三，我们将根据分销现状调整市场策略，为诊所提供入职培训和库存解决方案，为医院药房提供处方笺和总医疗成本解决方案，并透过谨慎包装和远端医疗咨询服务，优化我们的线上管道，以满足更年轻、更注重隐私的人群的需求。第四，我们将积极与付款人和公共卫生采购方沟通，强调持续照护、减少意外怀孕和生命週期依从性支持，而不仅仅是单价。最后，我们将实施真实世界证据计画和上市后安全监测，以维护监管信心并长期提升我们的产品定位。这些措施将打造一个兼顾临床可信度、营运韧性和管道有效性的持久成长平台。

我们透明的调查方法结合了主要相关人员访谈、监管和临床证据审查以及供应链分析，以形成策略见解

本研究整合了对临床医生、采购官员、临床专案经理和行业高管的初步定性访谈，并结合了对监管备案文件、临床试验註册中心以及主要医疗机构公开指南的结构化审查。受访者来自不同的地理、医疗机构和职位，旨在提供关于临床实践、采购考量和患者体验的客观视角。次要分析着重于政策公告、资费变化和供应链指标，以了解其对製造商和买家的营运影响。

资料综合采用主题分析，揭示政策、供应链弹性、临床应用和病患行为之间的交叉趋势和因果关係。用例描述了在供应商培训、筹资策略和管道赋能方面的成功干预措施。在适当情况下，纳入了敏感性考虑，以强调贸易政策、监管要求和临床指南的变化如何改变建议的优先事项。调查方法强调资讯来源类型的透明度和跨多个证据流的三角测量，以支持本报告中提出的策略建议。

结论性结论将创新、准入障碍和将产品进步转化为临床影响所需的营运重点联繫起来

总而言之，女性用避孕领域面临临床创新和系统可近性的双重挑战，需要商业性、临床和营运层面的综合应对。器械设计和配方的进步扩大了最终用户的选择，但其应用取决于临床医生的舒适度、分销能力和报销灵活性的相互作用。不断变化的贸易政策和关税调整使得供应链策略和区域生产考量日益重要，进而影响采购行为和产品定位。

为了应对这种环境，相关人员群体的生活现实来客製化通路策略。将研发、监管事务、商业策略和供应链管理连结起来的跨职能规划，对于将产品创新转化为持续的可及性和临床效益至关重要。本报告中的见解旨在为此类决策提供参考，并为有针对性的投资和伙伴关係提供实务基础。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 消费者对具有数位週期追踪功能的非荷尔蒙避孕设备的需求不断增加
  • 远距避孕远端医疗咨询激增，改善了服务不足地区的避孕服务
  • 可生物降解和无激素植入材料的进步减少了副作用和环境废弃物
  • 将基于人工智慧的生育预测工具整合到个人化避孕计画中
  • 男性避孕研究的扩展正在改变传统的市场动态和性别角色
  • 监管部门加速下一代避孕环和经皮吸收贴片产品核可
  • 数位健康Start-Ups与製药公司合作开发自我调整避孕解决方案

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

第八章女性用避孕药市场（依产品类型）

  • 植入
  • 注射
  • 子宫内避孕器
    • 铜子宫内避孕器
    • 荷尔蒙子宫内避孕器
  • 丸
    • 复方药丸
      • 第一代
      • 第四代
      • 第二代
      • 第三代
    • 仅含黄体素的药丸

第九章女性用避孕药市场（按机制）

  • 荷尔蒙
    • 组合
    • 仅含黄体素
  • 非荷尔蒙

第 10 章。以最终用户年龄组别分類的女性用避孕药市场

  • 15至24岁
  • 25-34岁
  • 35至49岁

第11章女性用避孕药市场按分销管道

  • 诊所
  • 医院药房
  • 网路药局
  • 零售药局

第十二章女性用避孕药市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章女性用避孕药市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章女性用避孕药市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Bayer Aktiengesellschaft
    • Organon & Co.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Johnson & Johnson
    • AbbVie Inc.
    • Viatris Inc.
    • Perrigo Company plc
    • Gedeon Richter Plc
    • Novartis AG
Product Code: MRR-4348D129FB2D

The Female Contraceptive Market is projected to grow by USD 16.53 billion at a CAGR of 6.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.91 billion
Estimated Year [2025] USD 10.57 billion
Forecast Year [2032] USD 16.53 billion
CAGR (%) 6.60%

A strategic introduction that frames clinical advances, stakeholder priorities, and access constraints shaping contemporary female contraceptive decision making

The contraceptive landscape for women is undergoing rapid evolution as clinical innovation, shifting provider practices, and changing patient expectations converge. This report opens with a concise framing of the contemporary environment, highlighting clinical modalities, distribution realities, regulatory pressures, and the practical constraints that shape access and adoption across care settings. It sets a pragmatic intellectual baseline for executives and clinical leaders by integrating recent advances in device and pharmaceutical options with observed patterns in provider preferences and patient decision-making.

The introduction contextualizes the competitive environment by emphasizing how technological improvements, patient-centered care models, and supply chain resilience intersect to determine where investment and operational attention are most valuable. It also clarifies the principal stakeholder groups-manufacturers, clinicians, payors, procurement teams, and patient advocacy organizations-and articulates the decision levers each group controls. Taken together, the framing prepares readers to interpret subsequent sections on structural shifts, policy impacts, segmentation nuances, regional dynamics, and recommended actions.

An analytical overview of the converging clinical, regulatory, and digital forces that are reshaping contraceptive practice patterns and patient access across care settings

The landscape for female contraception is being reshaped by a set of transformative forces that alter clinical practice, product development, and patient choice. New device designs and longer-acting formulations have expanded clinical options for different reproductive life stages, prompting clinicians to rethink counseling workflows and follow-up protocols. Concurrently, digital health tools and telemedicine have begun to change how contraceptive counseling, prescription, and follow-up are delivered, reducing geographic friction and enabling more patient autonomy in method selection.

In addition to technological and care-delivery changes, regulatory pathways and evidence expectations have evolved, raising the bar for clinical data but also creating clearer windows for incremental label expansions and novel indications. Competitive dynamics are shifting as firms pursue differentiated value propositions that emphasize ease of use, side effect profiles, and integrated care experiences rather than simple price competition. Finally, payor approaches and public health priorities are increasingly attentive to equity of access and adherence-support programs, encouraging stakeholders to design solutions that address systemic barriers to consistent, appropriate contraceptive use. Together, these shifts demand integrated commercial and clinical strategies that align product differentiation, reimbursement engagement, and provider education to capture sustained uptake.

A comprehensive analysis of how tariff adjustments in 2025 are reshaping supply chains, procurement strategies, and price pressures across contraceptive manufacturing and distribution

The policy environment in 2025 introduced tariff adjustments affecting imported pharmaceutical inputs and device components, and these changes have had compound effects on procurement, pricing dynamics, and supply chain configurations. Manufacturers that rely on internationally sourced electronic components for insertion devices or on active pharmaceutical ingredients produced abroad have faced immediate margin pressure, prompting discussions about nearshoring, supplier diversification, and inventory strategy. Purchasers and hospital systems have responded by revisiting supplier contracts and exploring longer cadence procurement arrangements to mitigate volatility.

These tariff-driven cost pressures have also influenced product lifecycle decisions. Development teams have increasingly prioritized process efficiencies and supplier consolidation to preserve product viability under higher landed costs. At the same time, public health programs and safety-net providers that operate on constrained budgets have sought supplemental funding models or procurement consortia to maintain access, particularly for long-acting reversible contraceptives that require specialized insertion training and device availability. Importantly, several manufacturers accelerated efforts to localize production of critical inputs and to redesign packaging and logistics to reduce cross-border tariff exposure, thereby enhancing resilience and shortening lead times.

From a demand perspective, clinicians and procurement leaders have indicated that even modest increases in delivered cost can influence method counseling preferences in settings where formularies and procurement guidelines are tightly restricted. Consequently, commercial teams must integrate tariff scenarios into procurement negotiations, pricing strategies, and value communications, highlighting total cost of care, adherence benefits, and downstream savings that resonate with payors and institutional buyers. Transitioning supply chains toward diversification and regional capacity represents a multi-year effort but one that is increasingly prioritized to stabilize access and maintain competitive positioning under shifting trade conditions.

In-depth segmentation insights that connect product types, hormonal mechanisms, age cohorts, and distribution channels to reveal targeted opportunities for clinical and commercial alignment

Effective segmentation illuminates where clinical benefit, patient preference, and commercial opportunity intersect within the contraceptive ecosystem. Product type distinctions remain essential: implants, injectables, intrauterine devices, and pills represent core clinical categories with distinct administration pathways and adherence profiles. Within intrauterine devices, the distinction between copper and hormonal options carries implications for side effect management, duration of effectiveness, and provider training. Pills encompass combined and progestin-only formulations, and within combined options there are generational differences-first, second, third, and fourth generation agents each present unique efficacy and tolerability trade-offs that influence prescriber selection.

Mechanism-based segmentation further clarifies demand dynamics by separating hormonal approaches from non-hormonal choices, and recognizing that hormonal options bifurcate into combined and progestin-only formulations with different contraindication profiles and counseling needs. Age-based end-user segmentation captures life-stage considerations: those aged 15 to 24 prioritize autonomy, convenience, and privacy; the 25 to 34 cohort often balances family planning goals with career and lifestyle considerations; and the 35 to 49 group places greater emphasis on long-term effectiveness, comorbidity considerations, and transition to non-hormonal alternatives as appropriate. Distribution channels shape access pathways, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each presenting distinct friction points and opportunities for education, adherence support, and aftercare.

Integrating these segmentation lenses reveals where targeted interventions can improve adoption and continuity. For example, long-acting modalities may resonate strongly with older age bands seeking minimal maintenance, while digital counseling and mail-order delivery can substantially lower access barriers for younger users who value discretion. Similarly, tailoring communications to mechanism-specific safety considerations and ensuring that distribution channels are equipped to support insertion or administration are critical operational priorities. By aligning product differentiation, clinical evidence generation, and channel enablement to the intersecting axes of product type, mechanism, age, and distribution, stakeholders can deploy more precise and effective strategies that address both clinical outcomes and user experience.

Key regional dynamics and policy contrasts across the Americas, Europe Middle East Africa, and Asia-Pacific that shape access, regulatory pathways, and distribution strategies

Geographic dynamics influence access, regulatory pathways, and competitive behavior across distinct regions, each presenting unique constraints and enablers. In the Americas, policy debates, payer structures, and diverse provider networks create both opportunities for rapid commercialization in well-resourced systems and ongoing access challenges in underserved populations. Regional procurement initiatives and advocacy programs have shaped uptake in public health clinics, while private payor negotiations dictate product positioning in higher-reimbursement settings.

Europe, Middle East & Africa presents a complex tapestry of regulatory environments and capacity differences. Some countries within this broad region have highly centralized procurement and stringent regulatory harmonization, enabling coordinated rollouts when approvals align. Other markets are fragmented, with variable clinical practice patterns and infrastructure that affect the feasibility of device-dependent contraceptives. Access programs and international donor initiatives remain influential in enabling broader distribution, especially for long-acting reversible methods in low-resource settings.

Asia-Pacific encompasses markets with substantial manufacturing capacity alongside rapidly evolving domestic demand. Regulatory agencies in several jurisdictions have accelerated reviews of contraceptive products and fostered local production capabilities, which can reduce lead times and exposure to international trade perturbations. However, cultural factors, provider practice norms, and heterogeneous reimbursement landscapes continue to shape adoption curves. Across all regions, stakeholders must adapt commercialization strategies to local regulatory structures, distribution ecosystems, and the policy priorities that influence procurement and patient access.

A practical analysis of how manufacturers, device specialists, and agile entrants are differentiating through clinical evidence, partnerships, and supply chain resilience

The competitive environment is populated by a mix of legacy pharmaceutical firms, specialized device manufacturers, and newer entrants leveraging service and digital ecosystems to enhance access. Leading firms focus R&D on improving tolerability and ease of use while investing in training programs to ensure clinician competence for device insertion and follow-up. Strategic partnerships between manufacturers and clinical networks have emerged as a pragmatic way to accelerate adoption, combining product supply with provider education and patient support services.

Smaller, agile companies are differentiating through novel delivery mechanisms, patient engagement tools, and targeted niche strategies aimed at specific age cohorts or clinical subpopulations. Contract manufacturing and component suppliers have also become pivotal players as firms seek to de-risk supply chains and maintain production flexibility. Additionally, procurement consortia and group purchasing organizations have increased their influence by negotiating longer-term supply agreements, which emphasizes the importance of predictable supply and value-based contracting for commercial success.

Across the competitive set, successful companies are those that link product attributes to demonstrable clinical and economic benefits, invest in post-market surveillance and real-world evidence, and create integrated value propositions that include clinician training and patient support. Operational excellence in manufacturing, regulatory strategy, and distribution is equally critical, as disruptions in any of those areas can quickly erode confidence among institutional buyers and clinicians.

Actionable strategic priorities for manufacturers and health system leaders to align evidence generation, resilient supply chains, and channel-specific commercial execution

Industry leaders should pursue a coordinated approach that aligns clinical evidence generation, supply chain resilience, and channel-specific commercialization. First, invest in robust comparative safety and tolerability data that speak directly to clinician concerns and patient-relevant outcomes, and pair that evidence with concise, clinician-friendly education modules to accelerate comfortable adoption of device-based and long-acting options. Second, prioritize supplier diversification and consider regional manufacturing investments or contract manufacturing partnerships to reduce exposure to trade policy shifts and input cost volatility.

Third, tailor go-to-market strategies to distribution realities by enabling clinics with insertion training and stocking solutions, supporting hospital pharmacies with formulary dossiers and total cost of care arguments, and optimizing online channels for privacy-focused younger cohorts through discreet packaging and telehealth-enabled counseling. Fourth, engage proactively with payors and public health purchasers using value narratives that emphasize continuity of care, reduced unintended pregnancies, and lifecycle adherence support rather than unit price alone. Finally, embed real-world evidence programs and post-market safety monitoring to sustain regulatory confidence and to refine product positioning over time. Taken together, these actions create a durable platform for growth that balances clinical credibility with operational resilience and channel effectiveness.

A transparent methodology combining primary stakeholder interviews, regulatory and clinical evidence review, and supply chain analysis to triangulate strategic insights

This research synthesizes primary qualitative interviews with clinicians, procurement directors, clinical program managers, and industry executives, coupled with a structured review of regulatory filings, clinical trial registries, and publicly available guidance from major health authorities. Interview subjects were selected to represent diverse geographies, care settings, and roles to provide a balanced view of clinical practice, procurement considerations, and patient experience. Secondary analysis focused on policy announcements, tariff changes, and supply chain indicators to contextualize operational implications for manufacturers and buyers.

Data synthesis employed thematic analysis to identify cross-cutting trends and causal linkages between policy, supply chain resilience, clinical adoption, and patient behavior. Case studies were used to illustrate successful interventions in provider training, procurement strategies, and channel enablement. Where appropriate, sensitivity considerations were discussed to highlight how changes in trade policy, regulatory requirements, or clinical guidelines could alter recommended priorities. The methodology emphasizes transparency in source types and triangulation across multiple evidence streams to support the strategic recommendations presented in this report.

A decisive conclusion drawing the connections between innovation, access barriers, and the operational priorities necessary to translate product advances into clinical impact

In conclusion, the female contraceptive space presents a blend of clinical innovation and systemic access challenges that require integrated commercial, clinical, and operational responses. Advances in device design and formulation expand options for end users, but adoption depends on the interplay of clinician comfort, distribution capacity, and reimbursement flexibility. Trade policy shifts and tariff adjustments have heightened the importance of supply chain strategy and regional production considerations, which in turn influence procurement behavior and product positioning.

To navigate this environment, stakeholders should prioritize evidence that aligns with clinician concerns, invest in resilient supply chains, and tailor channel strategies to the lived realities of different end-user cohorts. Coordinated cross-functional planning that connects R&D, regulatory affairs, commercial strategy, and supply chain management will be essential to translate product innovations into sustained access and clinical benefit. The insights in this report are intended to inform those decisions and to provide a practical foundation for targeted investments and partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing consumer demand for non-hormonal contraceptive devices with digital cycle-tracking integrations
  • 5.2. Surge in telehealth consultations for contraceptive care enhancing accessibility in underserved regions
  • 5.3. Advances in biodegradable and hormone-free implant materials reducing side effects and environmental waste
  • 5.4. Integration of artificial intelligence-powered fertility prediction tools into personalized contraceptive planning
  • 5.5. Expansion of male-focused contraceptive research shifting traditional market dynamics and gender roles
  • 5.6. Regulatory fast-tracking of next-generation vaginal rings and transdermal patches accelerating product approvals
  • 5.7. Collaborations between digital health startups and pharmaceutical firms for adaptive contraception solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Contraceptive Market, by Product Type

  • 8.1. Implants
  • 8.2. Injectables
  • 8.3. Intrauterine Devices
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD
  • 8.4. Pills
    • 8.4.1. Combined Pill
      • 8.4.1.1. First Generation
      • 8.4.1.2. Fourth Generation
      • 8.4.1.3. Second Generation
      • 8.4.1.4. Third Generation
    • 8.4.2. Progestin Only Pill

9. Female Contraceptive Market, by Mechanism

  • 9.1. Hormonal
    • 9.1.1. Combined
    • 9.1.2. Progestin Only
  • 9.2. Non-Hormonal

10. Female Contraceptive Market, by End User Age

  • 10.1. 15-24 Years
  • 10.2. 25-34 Years
  • 10.3. 35-49 Years

11. Female Contraceptive Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Female Contraceptive Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Female Contraceptive Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Female Contraceptive Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Bayer Aktiengesellschaft
    • 15.3.2. Organon & Co.
    • 15.3.3. Teva Pharmaceutical Industries Ltd.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. AbbVie Inc.
    • 15.3.7. Viatris Inc.
    • 15.3.8. Perrigo Company plc
    • 15.3.9. Gedeon Richter Plc
    • 15.3.10. Novartis AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FEMALE CONTRACEPTIVE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2024 (USD MILLION)
  • TABLE 320. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2025-2032 (USD MILLION)
  • TABLE 321. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2024 (USD MILLION)
  • TABLE 322. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025-2032 (USD MILLION)
  • TABLE 323. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 324. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 325. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. GCC FEMA